comparemela.com

Page 8 - Karls Dahlquist News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Congress Asset Management Co MA Acquires 10,649 Shares of AtriCure, Inc (NASDAQ:ATRC)

Congress Asset Management Co. MA boosted its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 10.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,094 shares of the medical device company’s stock after acquiring an […]

Congress Asset Management Co MA Raises Stock Position in AtriCure, Inc (NASDAQ:ATRC)

Congress Asset Management Co. MA grew its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 10.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,094 shares of the medical device company’s stock after purchasing an additional 10,649 shares […]

UBS Group Initiates Coverage on AtriCure (NASDAQ:ATRC)

Investment analysts at UBS Group initiated coverage on shares of AtriCure (NASDAQ:ATRC – Get Free Report) in a note issued to investors on Friday, FlyOnTheWall reports. The brokerage set a “buy” rating on the medical device company’s stock. A number of other brokerages also recently issued reports on ATRC. StockNews.com initiated coverage on shares of […]

Neuberger Berman Group LLC Has $31 23 Million Stock Holdings in AtriCure, Inc (NASDAQ:ATRC)

Neuberger Berman Group LLC increased its holdings in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 37.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 753,669 shares of the medical device company’s stock after buying an additional 204,175 shares during the quarter. Neuberger Berman Group LLC’s holdings in AtriCure were worth $31,225,000 at the end […]

AtriCure, Inc (NASDAQ:ATRC) Receives $66 80 Average PT from Brokerages

AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) has been given an average recommendation of “Buy” by the four analysts that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued ratings on the stock in the last […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.